P. Svenningsson, C. Le Moine, B. Kull, R. Sunahara, B. Bloch and B. B. Fredholm, “Cellular Expression of Adenosine A2A Receptor Messenger RNA in the Rat Nervous System with Special Reference To Dopamine Innervated Areas,” Neuroscience, Vol. 80, No. 4, 1997, pp. 11711185. doi:10.1016/S0306-4522(97)00180-2

has been cited by the following article:

• TITLE: Motor Effects of 1,3-Disubstituted 8-Styrylxanthines as A1 and A2 Adenosine-Receptor Antagonists in Rats

  AUTHORS: Ilhuicamina Daniel Limón-Pérez de León, María del Carmen Parra-Cid, Alejandro Muñoz-Zurita, Saúl Alejandro Merino-Contreras, Sara Montiel-Smith, Socorro Meza-Reyes, Gerardo Ramírez-Mejía, Jesús Sandoval-Ramírez

  KEYWORDS: Xantines; Adenosine Receptors Antagonists; Turning Behavior; Anti-Parkinsonian Drugs

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.4 No.3, June 4, 2013

  ABSTRACT: A series of 1,3-substituted 8-styrylxanthines (11a-d) was synthesized, under chemo- and regioselective conditions, in a good overall yield. The compounds showed affinity towards both A1 and A2A-adenosine receptors by radioligand binding by means of in vitro assays. The (E)-3-ethyl-1-propyl-8-styrylxanthine (11a) showed the greatest affinity towards the A2A receptor, whereas (E)-3-pentyl-1-propyl-8-styrylxanthine (11d) showed the greatest affinity for the A1 receptor. When the 8-styrylxanthines 11a (A15Et) and 11c (A15Bu) were administrated in rats, which were previously injured with 6-hydroxydopamine at the substantia nigra pars compacta (SNc), the turning behavior decreased 50%. Based on these results we propose to A15Et as a potential compound to treat some symptoms of Parkinson’s disease.